Zacks Investment Research upgraded shares of Miragen Therapeutics (NASDAQ:MGEN) from a hold rating to a buy rating in a report released on Friday, November 17th. They currently have $8.00 price objective on the medical research company’s stock.
According to Zacks, “Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. “
Other research analysts have also recently issued research reports about the company. Chardan Capital reiterated a buy rating on shares of Miragen Therapeutics in a research note on Monday, August 7th. Wedbush restated a buy rating on shares of Miragen Therapeutics in a research note on Friday, August 18th. Finally, ValuEngine cut Miragen Therapeutics from a hold rating to a sell rating in a research note on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $18.67.
Miragen Therapeutics (NASDAQ:MGEN) last announced its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.12. The business had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $0.72 million. Miragen Therapeutics had a negative return on equity of 80.31% and a negative net margin of 720.38%. research analysts anticipate that Miragen Therapeutics will post -1.39 EPS for the current year.
Several hedge funds have recently bought and sold shares of the company. Seaward Management Limited Partnership purchased a new position in shares of Miragen Therapeutics in the third quarter worth $117,000. Russell Investments Group Ltd. purchased a new position in shares of Miragen Therapeutics in the third quarter worth $147,000. BSW Wealth Partners purchased a new position in shares of Miragen Therapeutics in the third quarter worth $203,000. SG Americas Securities LLC purchased a new position in shares of Miragen Therapeutics in the third quarter worth $250,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Miragen Therapeutics in the first quarter worth $807,000. Hedge funds and other institutional investors own 22.64% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Miragen Therapeutics (MGEN) Upgraded at Zacks Investment Research” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2017/12/06/zacks-investment-research-upgrades-signal-genetics-inc-mgen-to-buy.html.
Miragen Therapeutics Company Profile
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.